Breaking Finance News

Vetr Inc. upgraded UnitedHealth Group Inc (NYSE:UNH) to Buy in a report released today.

Vetr Inc. has upgraded UnitedHealth Group Inc (NYSE:UNH) to Buy in a report released on 10/07/2016.

Yesterday UnitedHealth Group Inc (NYSE:UNH) traded 0.14% higher at $136.66. The company’s 50-day moving average is $137.80 and its 200-day moving average is $136.35. The last closing price is up 0.23% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 2,568,703 shares of the stock traded hands, down from an average trading volume of 2,943,200

See Chart Below

UnitedHealth Group Inc (NYSE:UNH)

UnitedHealth Group Inc has a 52 week low of $107.51 and a 52 week high of $144.48 with a P/E ratio of 21.39 UnitedHealth Group Inc’s market capitalization is currently $0.

In addition to Vetr Inc. reporting its stock price target, a total of 24 brokerages have issued a ratings update on the company. The average stock price target is $144.17 with 10 firms rating the stock a strong buy, 12 firms rating the stock a buy, 3 firms rating the stock a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the stock a sell.

More About UnitedHealth Group Inc (NYSE:UNH)

UnitedHealth Group Incorporated is a diversified healthcare company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. The Company conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum. UnitedHealthcare provides healthcare benefits to a range of customers and markets through its UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement, UnitedHealthcare Community & State, and UnitedHealthcare Global businesses. Optum is a health services business serving the healthcare marketplace, including payers, care providers, employers, governments, life sciences companies and consumers, through its OptumHealth, OptumInsight and OptumRx businesses.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *